Clinical trials: Depression Symptom
Suicide, Mental Health Disorder
A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT05920252
- Testing
- Vira, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Ksana Health
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250614
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Sanofi
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250601
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Sanofi
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Patient Tolerability Study of GSK163090
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
- Trial name
- NCT00559299
- Testing
- GSK163090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Depression
Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
The purpose of this study is to determine if Vortioxetine 20 mg/day will lead to changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with executive functioning and memory during cognitive…
- Trial name
- NCT01607125
- Testing
- Vortioxetine (Lu AA21004)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Stress, Depression
Cocooned Moms Study
The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app.
- Conditions
- Stress, Depression, Pregnancy, Blood Pressure
- Trial name
- Cocooned Moms (NCT06968650)
- Testing
- Digital and Coordinated Maternial Care
- Where
- 2 sites in United States
- Volunteers
- 384 people
- Sponsor
- InovCares Connected Comprehensive Healthcare Corporation
Depressive Symptoms
Combination Therapy in Patients With Depression
The purpose of the study is to compare sertraline and atomoxetine/sertraline combination therapy in patients with persistent depressive symptoms.
- Trial name
- NCT00485862
- Testing
- Atomoxetine Hydrochloride, Sertraline
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Eli Lilly and Company
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Insomnia, Menopause Related Conditions
Targeting Insomnia to Prevent Depression in the Menopause Transition
This randomized clinical trial is focused on perimenopausal women who have difficulty sleeping. It will randomize digital cognitive behavioral therapy for insomnia (dCBT-I) or a sleep hygiene intervention (SHI).
- Trial name
- NCT07443644
- Testing
- digital cognitive behavioral therapy for insomnia, Digital sleep hygiene education
- Volunteers
- 230 people
- Sponsor
- SRI International
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
The main objective is to evaluate the pharmacokinetics comparative studies in a single dose, multiple dose
- Trial name
- NCT02785614
- Testing
- trazodone hydrochloride prolonged-release tablet, trazodone hydrochloride tablet
- Where
- Hong Kong
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Major Depressive Disorder
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
This study was a pharmacokinetic and safety evaluation of the S-adenosylmethionine formulation MSI-195, and a commercial comparator. The study was broken into two stages.
- Trial name
- NCT04623034
- Testing
- Ademetionine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- MSI Methylation Sciences, Inc.
Major Depressive Disorder
Study of NSI-189 for Major Depressive Disorder
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80…
- Trial name
- NCT02695472
- Testing
- 80 Milligrams NSI-189, 40 Milligrams NSI-189
- Where
- 13 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Safety Study of F2695 SR in Major Depressive Disorder
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
- Trial name
- LVM-MD-04 (NCT01034267)
- Testing
- F2695 SR
- Where
- 68 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.